Extended Data Fig. 5: Antitumour activity of GSK-LSD1 in mouse breast tumour models. | Nature Biomedical Engineering

Extended Data Fig. 5: Antitumour activity of GSK-LSD1 in mouse breast tumour models.

From: An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity

Extended Data Fig. 5: Antitumour activity of GSK-LSD1 in mouse breast tumour models.

a, Drug-treatment scheme of mouse breast tumour models. b-d, Gross dissected mammary tumour images (b), tumour growth (c) and weight (d) of the EO771 tumours from the tumour-bearing C57BL/6 mice treated with vehicle control, GSK-LSD1 (20 mg kg-1). e, Proportions of total T, CD4+ T, and CD8+ T cells in total immune (CD45+) cells in the EO771 tumours treated with control, GSK-LSD1. f, Percentage of active cells in total CD8+ T cells, indicated by GZMB+, IFNγ+, TNFα+ in flow cytometry analysis. g, IHC staining images of Ki67+ and cleaved Caspase 3+ cells in the tumour tissues. h,i, Quantitative results for (g). For statistical analysis of data, Two-sided Student’s t-test was used in (c,d,h,i) and two-way ANOVA test was used in (e,f). Data are presented as mean ± SD. ***, p < 0.001; ****, p < 0.0001; ns, no significance.

Source data

Back to article page